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Mouse epiblast stem cells (EpiSCs) are cultured with
FGF2 and Activin A, like human embryonic stem cells
(hESCs), but the action of the associated pathways
in EpiSCs has not been well characterized. Here,
we show that activation of the Activin pathway
promotes self-renewal of EpiSCs via direct activation
of Nanog, whereas inhibition of this pathway induces
neuroectodermal differentiation, like in hESCs. In
contrast, the different roles of FGF signaling appear
to be only partially conserved in the mouse. Our
data suggest that FGF2 fails to cooperate with
SMAD2/3 signaling in actively promoting EpiSC
self-renewal through Nanog, in contrast to its role
in hESCs. Rather, FGF appears to stabilize the
epiblast state by dual inhibition of differentiation to
neuroectoderm and of media-induced reversion to
a mouse embryonic stem cell-like state. Our data
extend the current model of cell fate decisions con-
cerning EpiSCs by clarifying the distinct roles played
by FGF signaling.
INTRODUCTION
hESCs, like mouse embryonic stem cells (mESCs), are derived
from the inner cell mass (ICM) tissue of preimplantation embryos.
Hence, both share a number of cellular characteristics, such as
pluripotency and self-renewal capability. The latter is controlled
by a network of transcription factors that serves to maintain the
undifferentiated ESC state, in part by promoting the expression
of ESC-specific genes and suppressing that of differentiation-
specific ones (Boyer et al., 2005; Chen et al., 2008; Kim et al.,
2008). The transcription factors OCT4, NANOG, and SOX2 are
of central importance in both human and mouse ESCs, because
silencing of their gene expression usually has deleterious effects
on the self-renewal machinery, i.e., leads to cellular differentia-
tion (Fong et al., 2008; Hay et al., 2004; Ivanova et al., 2006;
Zaehres et al., 2005).However, hESCs and mESCs differ markedly in their
responses to signaling pathways that support self-renewal (see
Figure S1 available online). mESCs require LIF/STAT3 signaling
for self-renewal and benefit from mimicking WNT/b-catenin
signaling with small-molecule GSK3b inhibitors (Niwa et al.,
2009; Sato et al., 2004). The FGF/ERK cascade plays a role in
the differentiation of mESCs, as evidenced, for example, by
the inability of Erk2/ ESCs to differentiate along somatic cell
lineages (Kunath et al., 2007). Thus, mESCs can be maintained
in culture in a highly undifferentiated state by manipulating these
pathways: i.e., by adding LIF, a GSK3b inhibitor, and a MEK
inhibitor to inactivate FGF/ERK signaling (Figure S1; Guo et al.,
2009; Ying et al., 2008).
In contrast, hESCs do not respond to LIF (Dahe´ron et al.,
2004). WNT/b-catenin signaling induces hESC differentiation
under chemically defined conditions (Sumi et al., 2008), and
FGF/ERK signaling promotes self-renewal. Virtually all hESC
media described to date contain FGF2 (e.g., Dvorak et al.,
2005; Furue et al., 2008; Levenstein et al., 2006; Xu et al.,
2005; Yao et al., 2006). However, FGF2 supplementation has
been associated with pleiotropic-positive effects: impeding
spontaneous differentiation, increasing hESC proliferation,
enhancing attachment/survival, inhibiting earliest neural induc-
tion, and, more precisely, moderately stimulating NANOG gene
expression (Eiselleova et al., 2009; Greber et al., 2007, 2008; Li
et al., 2007; Ludwig et al., 2006; Wang et al., 2009). Furthermore,
FGF2 also exerts its effects through indirect mechanisms, via
cells cocultured with hESCs (Bendall et al., 2007; Greber et al.,
2007). For instance, FGF2 may stimulate mouse embryonic
fibroblasts (MEFs)—which are frequently used as feeder
layers—to secrete Activin A (ActA; Greber et al., 2007). ActA
belongs to the TGF-b family of ligands and promotes activation
of the SMAD2/3 transcription factors, which is considered bene-
ficial for hESC self-renewal (Figure S1; James et al., 2005; Vallier
et al., 2005). SMAD2/3 has been found to bind to the NANOG
promoter and thereby activate NANOG gene transcription, es-
tablishing a direct link between a signaling pathway and the self-
renewal network in hESCs (Greber et al., 2008; Xu et al., 2008).
EpiSCs are derived from the pluripotent epiblast tissue of early
postimplantation mouse embryos (Brons et al., 2007; Tesar
et al., 2007). These cells express Oct4, Nanog, and Sox2 andCell Stem Cell 6, 215–226, March 5, 2010 ª2010 Elsevier Inc. 215
Figure 1. Generation of Epiblast Stem Cells
(A) Top: Oct4-expressing outgrowth 3 days after plating day
5.5 epiblasts on MEFs. Bottom: Morphology of line 3 estab-
lished from hybrid strain embryos.
(B) Real-time RT-PCR analysis of marker gene expression in
E3 EpiSCs and mouse ESCs. Bars reflect normalization error.
(C) 4-week-old teratoma generated from line 3 and HE-stained
sections showing in vivo differentiation along all three germ
layers.
(D) Global gene expression comparison of E3 EpiSCs, ESCs,
and line 9 EpiSCs from Tesar et al. (2007). Right: Dendogram
based on linear correlation coefficients (r).
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Roles of SMAD2/3 and FGF Signaling in EpiSCsexhibit features of pluripotency both in vitro and in teratoma
assays. Moreover, they display flattened colony morphology
similar to that of hESCs. Furthermore, they are derived and main-
tained under conditions that also support hESC self-renewal—
with FGF2 on inactivated MEFs or with FGF2 and ActA under
feeder-free conditions. These findings suggest that human
ESCs may rather correspond to cells of a postimplantation/
pregastrulation stage of mammalian development. Indeed,
pathways driving directed hESC differentiation appear to be
consistent with this concept (Murry and Keller, 2008).
However, in addition to their blastocyst origin, hESCs share
several molecular features with mESCs, but not with EpiSCs.
These include the expression of the ICM marker gene REX1 as
well as the lack of expression of the epiblast-specific FGF5
gene (Adjaye et al., 2005; Darr et al., 2006; Pelton et al., 2002).
Moreover, the transcription factor KLF4 has been shown to be
vital for the direct reprogramming of human somatic cells to an
ESC-like state, and KLF4 is expressed and functional in hESCs
(Chan et al., 2009; Nakagawa et al., 2008). Klf4 is also expressed
in mESCs but almost completely silenced in EpiSCs, and Klf4
overexpression has been shown to result in the reversion of
EpiSCs back to an ESC-like state (Guo et al., 2009).
The mouse is the most important model organism for gener-
ating hypotheses about how to maintain and differentiate human
ESCs. And, because EpiSCs may represent an important link
between human ESCs and the mouse embryo, significant infor-
mation can be gained by better defining the relationship between
hESCs and EpiSCs. To this end, we have characterized the roles
of SMAD2/3 and FGF/ERK signaling in EpiSCs. We find that
SMAD2/3 signaling directly controls Nanog expression in
EpiSCs, as in hESCs, despite the low conservation of SMAD2/
3/4 binding sites in the mouse Nanog promoter. Surprisingly,
with respect to FGF/ERK signaling, FGF2 fails to actively support
self-renewal in EpiSCs via Nanog expression, in contrast to its
role in hESCs. Rather, it supports the EpiSC state by inhibiting216 Cell Stem Cell 6, 215–226, March 5, 2010 ª2010 Elsevier Inc.lineage commitment. On the one hand, FGF2
appears to inhibit neural induction; on the other
hand, it helps impede reversion to an ESC-like
state by suppressing Klf2.
RESULTS
Generation of Epiblast Stem Cells
EpiSCs were established from day 5.5 hybrid
embryos under hESC culture conditions (GOF18-GFP 3 129Sv; Amit et al., 2004; Yoshimizu et al., 1999). One
karyotypically normal line, termed E3, was used for most further
investigations (Figure 1A). E3 expressed the pluripotency genes
Oct4, Nanog, and Sox2 at levels comparable to those in mouse
ESCs. As expected, however, the epiblast marker Fgf5 was
strongly upregulated, whereas the mESC-specific genes Rex1,
Esrrb, Klf4, and others were expressed at much lower levels
than in mESCs (Figure 1B). Upon injection into immunocompro-
mised mice, the E3 cells readily gave rise to teratomas contain-
ing differentiated derivatives of all three germ layers (Figure 1C).
Furthermore, the cells preferentially used the epiblast-specific
proximal enhancer to drive Oct4 expression, exhibited insensi-
tivity to inhibition of the LIF/STAT3 pathway, yet displayed
sensitivity to suppression of SMAD2/3 signaling (see below;
Tesar et al., 2007; Yeom et al., 1996). Finally, global gene expres-
sion analysis revealed that E3 cells were very similar to EpiSCs
that had been independently derived in a different laboratory
(Figure 1D; Table S1, line T9). We therefore conclude that the
E3 cells are bona fide EpiSCs.
Nanog Is aDirect Target of SMAD2/3 Signaling in EpiSCs
Although SMAD2/3 directly regulates NANOG expression in
human ESCs (Greber et al., 2008; Vallier et al., 2009a; Xu et al.,
2008), most (putative) SMAD2/3/4 binding sites are not
conserved in the mouse (Figure S2D). We therefore sought to
investigate this point in EpiSCs. We first attempted to grow
EpiSCs under feeder-free conditions in MEF-conditioned
medium that contained physiological levels of ActA to stimulate
SMAD2/3 signaling (Figures S1 and S2A). E3 EpiSCs were found
to grow robustly as flat colonies, with minimal differentiation
(Figure 2A). Oct4, Nanog, and Sox2 levels were comparable to
those in cultures on MEFs. However, when SMAD2/3 signaling
was blocked for 12 hr, by treatment with SB431542 (SB; Fig-
ure S1), NANOG, but not OCT4 or SOX2, protein levels decreased
substantially (Figure 2B). To assess whetherNanog expression is
Figure 2. Nanog Is a Direct Target of SMAD2/3 Signaling in EpiSCs
(A) Undifferentiated morphology in MEF-conditioned medium.
(B) Western blot of EpiSCs grown/treated as indicated.
(C) RT-qPCR after growing EpiSCs in defined medium with the indicated supplements. Bars reflect normalization error.
(D) RT-qPCR of EpiSCs in KSR medium treated as indicated.
(E) RT-qPCR of SB-starved and restimulated samples. Cycloheximide was added for 2 hr to both the control and restimulated samples. Bars reflect
normalization error.
(F) ChIP-qPCR with two primer pairs spanning a putative SMAD2/3 binding site in the Nanog promoter, as illustrated in Figure S2D. Left: EpiSCs harvested under
SMAD2/3-stimulating conditions. Right: Cells pretreated for 2 hr with SB. Bars reflect normalization error.
(G) Luciferase assay with wild-type and mutated Nanog promoter fragments illustrated in Figure S2D. Note that SB treatment of EpiSCs significantly reduced
activity only when the putative SMAD2/3 binding site was intact. Bars: SEM between biological duplicates.
(H) Conventional RT-PCR (30 cycles).
(I) Western blot after Nodal knockdown in EpiSCs grown for 3 days in the indicated media.
See also Figure S2 for additional data.
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Roles of SMAD2/3 and FGF Signaling in EpiSCssupported in a paracrine manner by ActA, EpiSCs were trans-
ferred to defined medium at a low density and exposed to
varying doses of ActA. Indeed, the Nanog expression level corre-
lated with the ActA concentration in the medium (Figure 2C).
A direct connection between the activity of a signaling
pathway and target gene expression can be elucidated by as-
sessing corresponding transcriptional responses over the short
term. In EpiSCs, Nanog expression was found to drop by 70%within 3 hr of treatment with SB. Upon restimulation with ActA,
Nanog expression was immediately induced. Oct4, however, ex-
hibited almost no short-term response (Figure 2D). A very similar
pattern was obtained with two other EpiSC lines (Figure S2B).
Moreover, Nanog expression in mouse ESCs was unaffected
by SB treatment, suggesting that sensitivity to SMAD2/3 inhibi-
tion is a defining feature of EpiSCs (Figure S2C). The short-
term induction of Nanog in SB-starved EpiSCs did not requireCell Stem Cell 6, 215–226, March 5, 2010 ª2010 Elsevier Inc. 217
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Roles of SMAD2/3 and FGF Signaling in EpiSCsnew protein synthesis because it also occurred in the presence
of cycloheximide (Figure 2E). We therefore performed ChIP-
qPCR with a phospho-SMAD2/3 antibody to determine whether
control of Nanog expression is mediated by direct Nanog
promoter occupancy. Two amplicons spanning the only putative
SMAD2/3/4 binding site in the mouse Nanog promoter showed
enrichment over input and over a downstream negative control
region under SMAD2/3-activating conditions (Figure 2F; Fig-
ure S2D). Importantly, these signals were abolished under
SMAD2/3-inactivating conditions, confirming their specificity
(Figure 2F). To assess the functionality of the putative SMAD2/
3/4 binding site, wild-type and mutated Nanog promoter frag-
ments (Figure S2D) driving luciferase expression were trans-
fected into EpiSCs under SMAD2/3-activating and -inactivating
conditions. As expected, the wild-type construct exhibited
significantly higher activity than the mutated one under
SMAD2/3-activating conditions, but the difference in activity
became insignificant under inactivating conditions, suggesting
that the site is indeed SMAD2/3 responsive (Figure 2G).
When passaged as clumps, at a sufficient density, E3 EpiSCs
actually did not require ActA supplementation to remain in an
undifferentiated state. Only when cells were plated as smaller
clumps, at a low density, was Nanog expression reduced (Fig-
ure S2E). This suggested that autocrine signaling stimulating
SMAD2/3 is operative in these cells. Nodal appears to be the
factor most probably mediating this effect, because the ActA
gene is not expressed in EpiSCs, in contrast to hESCs (Fig-
ure 2H). To confirm this notion, we silenced Nodal expression,
via RNA interference, and found that it resulted in Nanog down-
regulation and EpiSC differentiation (Figure S2F). Interestingly,
Nodal knockdown appeared to affect terminal SMAD3 rather
than SMAD2 phosphorylation, suggesting selective effector
usage by autocrine Nodal (Figure 2I, right). In contrast, when
cells were grown in conditioned medium (which contains ActA)
or unconditioned medium plus recombinant ActA, the knock-
down phenotype was at least partially rescued, demonstrating
that paracrine factors can substitute for autocrine Nodal
(Figure 2I, left; Figure S2F). Taken together, these findings indi-
cate that SMAD2/3 signaling directly controls Nanog expression
in EpiSCs.
FGF Signaling Inhibits Neural Commitment in EpiSCs
We next investigated how FGF2 may support EpiSC self-renewal.
In MEF-dependent culture, FGF2 induces ActA secretion from
the feeder layer, which may overshadow its direct effects on
EpiSCs (Figure S2A). Alternatively, E3 EpiSCs could also be
maintained in an undifferentiated state in defined N2B27 medium
supplemented with FGF2 alone (Figure 3A; Yao et al., 2006).
Although the rates of spontaneous differentiation, particularly
with lines T9 and E5, appeared to be somewhat higher than in
MEF-conditioned medium, N2B27 medium allowed assessment
of FGF-mediated effects over the short term.
To test whether FGF2/ERK signaling enhances EpiSC survival,
a cell attachment test was performed. Addition of a ROCK inhib-
itor was found to increase survival by about 5-fold (Watanabe
et al., 2007). However, FGF2 addition also significantly enhanced
attachment/survival after single-cell/small-clump dissociation,
which EpiSCs do not tolerate well, and FGF pathway inhibition
appeared to reduce cell survival to some extent (Figure 3B). To218 Cell Stem Cell 6, 215–226, March 5, 2010 ª2010 Elsevier Inc.assess whether FGF signaling also stimulates cell proliferation,
cell growth was examined. No significant difference between
the numbers of cells grown with FGF2 versus those grown
without FGF was observed, suggesting that FGF2 supplementa-
tion has no effect on cell proliferation in EpiSCs (Figure 3C).
To test effects over a longer period, we exposed EpiSCs to
FGF/ERK inhibitors ‘‘SU’’ or ‘‘PD’’ (see Figure S1) continuously.
In line with the data in Figure 3B, we noticed increased cell death
and also differentiation in the presence of FGF/ERK inhibitors.
Global transcription profiles were recorded at passage 2 to
investigate differential gene expression in comparison with
FGF2-treated control cells. Gene ontology analysis revealed
that the gene set upregulated with SU and PD was highly en-
riched in terms associated with neural development, raising the
possibility that FGF signaling in EpiSCs may act to inhibit differ-
entiation into that lineage (Figure S3A). Of note is that inhibition of
neural induction by FGF signaling has also been observed in
hESCs. In particular, PAX6 induction appeared to be repressed
by the addition of FGF2 to the medium (Greber et al., 2008).
We have reproduced these data with a different hESC line,
HuES6 (Figure S3B).
We therefore assessed whether a similar effect on the induc-
tion of early neuroectodermal genes occurs in EpiSCs. When
neuroectodermal differentiation was permitted by inhibiting
SMAD2/3 signaling (to suppress Nanog) in the presence of
FGF2, the markers Sox2 and Sox1 were indeed clearly induced.
However, without FGF2 addition, Sox2 and Sox1 upregulation
was at least equally pronounced and, strikingly, Pax6 induction
was significantly stronger (Figure 3D). A similar pattern was
observed with inhibitors to completely inactivate FGF/ERK
signaling (Figure S3C). The preferred induction of Pax6 in the
absence of FGF signaling was confirmed at the protein level
via immunocytochemistry (Figure 3E). To assess whether
terminal differentiation is also affected, induced cultures were
left untreated for 2 more days and then stained for the neuronal
marker b-III-Tubulin. Neurons readily formed after induction with
SB + FGF2 or SB + PD. Their numbers, however, appeared to be
higher after SB + PD pretreatment. Similar results were obtained
with SU to suppress FGF signaling (not shown). Moreover, many
neurons formed even upon continuous SB + PD treatment and,
again, the numbers were higher than those after exposure to
SB + FGF2 (Figure S3E). According to gene expression analysis,
the difference in neuronal marker gene expression was several-
fold (Figure S3F). In conclusion, FGF signaling inhibits, but does
not fully block, neuroectodermal induction in EpiSCs, similar to
the situation in hESCs (Figure S3B).
FGF Signaling Does not Support Nanog Expression
in EpiSCs
The above FGF-mediated effects may be beneficial for hESC/
EpiSC maintenance, but they are not strictly associated with
promoting self-renewal. For any bona fide self-renewal factor,
one may postulate a positive effect on the transcription factor
network controlling self-renewal and pluripotency. Indeed, there
are indications that this also applies to FGF2 signaling in hESCs
and, interestingly, OCT4 has been suggested to control FGF2
expression (data in Boyer et al., 2005). In contrast, it appears
that Fgf2 is not expressed in EpiSCs (Figure 4A). By using
ChIP-qPCR, we confirmed the binding of OCT4 to the FGF2
Figure 3. Characterization of Putative Effects of FGF Signaling in EpiSCs
(A) Representative morphology and OCT4 immunostain of E3 EpiSCs grown in defined medium with FGF2 (passage 5). Two other lines used showed more
abundant spontaneous differentiation.
(B) Cell attachment test in the presence of the indicated molecules. The right panel validates the assay. Bars: SEM between independent biological replicates.
(C) Growth test in the presence and absence of exogenously added FGF2. Bars: SEM between independent biological replicates.
(D) RT-qPCR for early neuroectodermal markers after the indicated treatments. Note that Sox1 induction is mostly attributable to SB treatment, whereas Pax6
induction appears to be a preferential effect of FGF2 withdrawal. Bars: SEM between independent biological replicates.
(E) Representative immunostains for PAX6 and class III b-Tubulin after the indicated treatments of E3 EpiSCs in N2B27 medium.
See also Figure S3 for additional data.
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orthologous region in EpiSCs (Figure 4B; Figure S4A).
It has been noted that in hESCs, not only does SMAD2/3
support NANOG expression, but so does FGF signaling,
whereas the mechanism linking NANOG expression and FGF
signaling is poorly understood (data in Greber et al., 2007,
2008; Wang et al., 2009). This was confirmed with independent
batches of hESCs via short-term FGF/ERK inhibition and two
sets of NANOG qPCR primers. Irrespective of the FGF/ERK
cascade inhibitor or PCR amplicon used, FGF/ERK inhibition
caused a 50% decrease in NANOG mRNA levels within 12 hr.
The effect of SMAD2/3 inhibition was stronger (85% decrease),
but additional FGF receptor blockage caused a further drop in
NANOG expression, indicating cooperation between the two
pathways (Figure 4C). The dependence of NANOG expression
on FGF/ERK signaling in hESCs was also confirmed at the
protein level (Figure 4E). In stark contrast, no effect on Nanog
expression was observed in similar experiments with EpiSCs(Figures 4D and 4F; Figure S4B). This was also confirmed with
an independent EpiSC line (Figure S4B). We conclude that FGF
signaling in cooperation with SMAD2/3 signaling mediates
NANOG expression in hESCs, thereby actively promoting self-
renewal. However, EpiSCs appear to respond only to SMAD2/
3 activation.
Dedifferentiation of EpiSCs to an ESC-like State
Is Cooperatively Promoted by FGF/ERK Inhibition,
GSK3b Inactivation, and LIF/STAT3 Stimulation
In addition to self-renewing or differentiating along somatic cell
lineages, EpiSCs have another option in culture: they can revert
back to an ESC-like state. This was first shown by Klf4 overex-
pression (Guo et al., 2009). However, data in a recent report
suggest that switching to stringent mESC culture conditions
alone supports this reversion (in Hanna et al., 2009). Interest-
ingly, this medium contains—in addition to LIF and a GSK3b
inhibitor (‘‘CH’’)—a MEK inhibitor to inactivate the FGF/ERKCell Stem Cell 6, 215–226, March 5, 2010 ª2010 Elsevier Inc. 219
Figure 4. Suppression of FGF Signaling Does Not Affect Nanog
Expression in EpiSCs
(A) Conventional RT-PCR (30 cycles).
(B) OCT4 ChIP-qPCR with primers spanning a putative binding site in the
human FGF2 locus, as illustrated in Figure S4A. Right: OCT4 fails to bind to
the orthologous region in EpiSCs. Binding to the Nanog promoter was used
as a positive control. Bars: left, normalization error; right, SEM of four indepen-
dent experiments.
(C) Reduction of NANOG mRNA after short-term FGF/ERK suppression in
hESCs (H1). Note that even upon suppression of SMAD2/3 signaling (SB),
FGF/ERK inhibition causes a further decrease in NANOG message. In compar-
ison, there was only a slight decrease in OCT4 expression (not shown). Bars
reflect normalization error.
(D) Quantification of Nanog mRNA in E3 EpiSCs grown in two different media.
Bars: SEM between two or three independent replicates per treatment.
(E) Western blot with hESCs treated as indicated in defined medium.
(F) Western blot with EpiSCs treated as indicated in defined medium.
See also Figure S4 for additional data.
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Roles of SMAD2/3 and FGF Signaling in EpiSCscascade (PD, see Figure S1). We hypothesized that this may in
turn suggest another role for FGF/ERK signaling: to stabilize
the epiblast state by preventing dedifferentiation.
To assess this, E3 EpiSCs were seeded onto MEFs as small
clumps and treated separately with PD, CH, and LIF. Cells
treated with CH showed overt differentiation, whereas cultures
treated with PD or LIF still formed flat EpiSC-like colonies. How-
ever, for each condition, small dome-shaped colonies were also
seen to emerge within 3 days. Interestingly, when added in
combination, many more—about one third of the total—demar-220 Cell Stem Cell 6, 215–226, March 5, 2010 ª2010 Elsevier Inc.cated ESC-like colonies had formed (Figure 5A). Splitting these
PD/CH/LIF-treated cultures via single-cell dissociation enriched
for these cells, whereas differentiated ones appeared to become
outcompeted. After 1 or 2 passages, the cultures were homoge-
neous and morphologically indistinguishable from those of
mESCs (Figure 5A). The new cells, termed E3R, could be grown
on gelatin and stained strongly positive for alkaline phosphatase,
in contrast to E3 EpiSCs (Figures 5A and 5B). Via markers to
distinguish mESCs and EpiSCs, these cells were found to
display a typical mESC profile (Figure 5C). Like mESCs, E3R
cells showed activity of the distal Oct4 enhancer, whereas
parental E3 EpiSCs preferentially used the epiblast-specific
proximal enhancer (Figure 5D; Yeom et al., 1996). EpiSCs were
sensitive to inhibition of SMAD2/3, whereas E3R and ESCs
were not (Figure 5E). In contrast, E3R and ESCs displayed
downregulation of ESC markers upon LIF/STAT3 inhibition,
whereas EpiSCs showed no response (Figure 5F). Global gene
expression analysis revealed that E3R cells clustered together
with ESCs but not with parental EpiSCs (Figure 5G). Finally,
upon combination with preimplantation embryos, E3R cells
gave rise to high-contribution coat color chimeras, followed by
germline transmission, which demonstrates mESC-like pluripo-
tency (Figure 5H).
We also performed similar experiments to revert T9 EpiSCs
(mostly 129 inbred background). The efficiency of reversion to
ESC-like colonies was found to be substantially lower than that
with E3 EpiSCs, but the reverted cells were robust in the sense
that they could be maintained with LIF alone (Figures S5A–
S5C). We could also revert a third line, E5, or replace PD by an
alternative FGF inhibitor (SU), suggesting that the procedure it-
self is robust (Figures S5D and S5E). In contrast to reverted T9
EpiSCs, E3R cells (hybrid background) required the continuous
presence of PD, CH, and LIF to maintain the ESC state, consis-
tent with observations with ESCs from so-called nonpermissive
backgrounds (Figure S5F; Hanna et al., 2009). Taken together,
these findings suggest that EpiSCs can be reverted to an ESC-
like state at variable efficiency, simply by switching to stringent
mouse ESC culture conditions.
Klf2 Is a Repressed Target of FGF Signaling
in EpiSCs and ESCs
Because reversion of the E3 EpiSC line was very efficient, we
thought it should be possible to track the induction of ESC-
specific gene expression after treatment with different mole-
cules. First, we harvested samples from bulk cultures treated
with PD, CH, and LIF alone or in combination for 3 days—i.e.,
when ESC-like colonies first become apparent (Figure 5A). The
induction of ESC-specific markers was indeed readily detect-
able. At the same time, markers for somatic and extraembryonic
differentiation were found to be upregulated. This was mostly
attributable to the addition of CH, because EpiSCs with LIF alone
did not exhibit much differentiation (Figures 5A and 6A). In
contrast, the three molecules appeared to cooperate in the
induction of mESC-specific markers, consistent with the
increase in ESC-like colony numbers when the molecules were
used in combination (Figures 5A and 6A). To quantify this coop-
erativity and to confirm that FGF/ERK inhibition also makes a
contribution to the reversion of EpiSCs, ESC-like alkaline phos-
phatase-positive colonies were scored after 4 days of treatment
Figure 5. Reversion of E3 EpiSCs to an ESC-
like State by Switching Culture Conditions
Involving FGF/ERK Suppression
(A) Morphology on MEFs after 3 days of the indi-
cated treatments. Arrows point at colonies of
domed ESC-like appearance. Bottom right:
Morphology of E3R cells compared with mESCs,
and under feeder-free conditions.
(B) Alkaline phosphatase stain. Both samples were
incubated for the same time.
(C) RT-qPCR marker expression analysis.
(D) Luciferase assay for relative Oct4 enhancer
activities.
(E) RT-qPCR analysis after the indicated treat-
ments.
(F) RT-qPCR analysis after the indicated treat-
ments.
(G) Global expression profiles and clustering
based on linear correlation coefficients (r).
(H) Top: Chimeric mice obtained after morula
aggregation with E3R cells. Chimerism is indicated
by dark donor coat color on white CFW host back-
ground. Six of nine offspring were obvious coat
color chimeras. In contrast, after aggregation of
parental E3 EpiSCs, only 2 out of 31 mice born dis-
played (very low) coat color chimerism (not
shown). Bottom: Embryonic and live offspring of
male chimera shown on top. Germline transmis-
sion is indicated by Oct4-GFP transgene-medi-
ated fluorescence, as well as coat color and PCR
genotyping of the pup shown.
See also Figure S5 for additional data.
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CH or LIF, PD treatment significantly enhanced reversion effi-
ciencies. In contrast, FGF treatment greatly diminished the
formation of ESC-like colonies, suggesting that FGF/ERK sig-
naling indeed serves to prevent the dedifferentiation of EpiSCs
(Figure S6).
To determine whether the three-molecule-mediated reversion
of EpiSCs comprises an inductive rather than a selective
process, we performed short-term treatment for just 3 hr and
determined the effect on downstream gene expression. Alter-
ation in the expression of direct target genes of the respective
pathways was observed: Egr1, downregulated with PD treat-
ment; T, upregulated with CH treatment (Arnold et al., 2000);
and Socs3, upregulated with LIF treatment (Table S3). Strikingly,
Klf2, a direct reprogramming factor (Nakagawa et al., 2008),
turned out to be induced by FGF/ERK inhibition but its upregula-
tion was even stronger with PD/CH/LIF treatment (Figure 6B;
Table S3). We performed the same treatments for two more
time points and assessed the results by array and real-time
analysis to confirm these findings. As shown in Figure 6C,
Klf2—but not Klf4—became gradually induced over time.
Intriguingly, the molecules appeared to synergize/cooperate in
activating Klf2: FGF/ERK inhibition had an immediate-early
effect, whereas CH treatment accounted for activation at later
time points (Figures 6A and 6C; Tables S3 and S4). Considering
that Klf2 can substitute for Klf4 in direct reprogramming (Naka-
gawa et al., 2008) and that Klf4 or Klf2 overexpression is suffi-cient to revert EpiSCs to an ESC-like state (Guo et al., 2009;
Hall et al., 2009), these data suggest that there may be an induc-
tive mechanism regulating medium switch-based EpiSC rever-
sion. To substantiate this hypothesis, we silenced Klf2 in EpiSCs
by using RNA interference, which did not interfere with EpiSC
self-renewal, as expected. Compared with controls, the Klf2
knockdown cells indeed reverted at substantially lower effi-
ciency (Figure 6D). Hence, induction of Klf2 by the PD/CH/LIF
cocktail correlates with ESC-like colony formation efficiency
and, moreover, endogenous Klf2 is required for PD/CH/LIF-
mediated EpiSC reversion.
The fact that EpiSCs could be reverted to ESC-like cells by
manipulating the activities of three signaling pathways prompted
us to ask whether the opposite treatments would support the
formation of epiblast cells from ESCs. This question was also
motivated by the fact that LIF treatment did not lead to induction
of Klf4 expression in EpiSCs, although activation of this pathway
has been found to sustain Klf4 expression in mESCs (Figure 6C;
Hall et al., 2009; Niwa et al., 2009). With an emphasis on the LIF/
STAT3 and FGF/ERK pathways, we therefore carried out the
complementary stimulation/inhibition experiments: To exclude
autocrine effects, mESCs were grown in LIF plus PD and then
treated for 12 hr with (1) FGF + LIF, (2) a JAK inhibitor + PD,
and (3) a JAK inhibitor + FGF. Consistent with the finding that
suppression of FGF/ERK signaling leads to Klf2 induction in
EpiSCs, FGF/ERK stimulation in mESCs resulted in moderate
but significant Klf2 suppression (Figure 7A; Table S5). InCell Stem Cell 6, 215–226, March 5, 2010 ª2010 Elsevier Inc. 221
Figure 6. Early Gene Expression Signatures
in Reverting EpiSCs
(A) RT-qPCR analysis in EpiSCs treated in
KSR medium supplemented with the indicated
molecules. Note the cooperativity between the
three molecules in inducing ESC-specific gene
expression.
(B) Analysis of global gene expression changes in
EpiSCs stimulated with PD, CH, and LIF alone or in
combination (PCL) for 3 hr. Gene symbols in gray
are known downstream targets of the manipulated
pathways. At this time point, Klf2 was induced by
PD but not by CH or LIF treatment.
(C) RT-qPCR analysis of EpiSCs stimulated for
different time periods in the indicated ways. Note
that Klf2, but not Klf4, consistently shows syner-
gistic/cooperative induction at all time points.
Bars reflect normalization error.
(D) Reversion of E3 EpiSCs after Klf2 knockdown.
Left: typical morphology 4 days after seeding on
MEFs in PD/CH/LIF-containing medium. Middle:
macroscopic view of AP-stained dishes at day 4.
Right: quantification of reversion efficiency based
on AP-positive colony numbers. EpiSC self-
renewal was unaffected by the Klf2 knockdown
as judged by unaltered Oct4 expression levels
before seeding. The Klf2 knockdown efficiency in
the ‘‘polyclonal’’ EpiSC population was about
65% (data not shown).
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Roles of SMAD2/3 and FGF Signaling in EpiSCscomparison, LIF stimulation did not lead to Klf4 induction in
EpiSCs (Figure 6C), but inhibition of the LIF/STAT3 pathway
led to significant Klf4 repression in mESCs (Figure 7A). The
same treatments were applied to cultures on feeder layers—
which are compatible with both ESC and EpiSC growth. Both
FGF treatment and inhibition of LIF/STAT3 signaling led to an
EpiSC-like colony morphology—i.e., flattening of the mESC
colonies—within 2 days, whereas combined treatment pro-
duced this effect even earlier (Figure 7B and not shown). Real-
time PCR analysis revealed again that Klf2 suppression
correlated with FGF/ERK stimulation and that Klf4 suppression
correlated with LIF/STAT3 inhibition. Consistent with the above
morphological changes, LIF/STAT3 inhibition led to a strong
induction of the expression of epiblast marker Fgf5, whereas
FGF/ERK stimulation also contributed to this effect, resulting in
highest Fgf5 levels with combined treatment (Figures 7B and
7C). In conclusion, ES and epiblast cell states can be converted
into each other in vitro by manipulating the activities of a set of
signaling pathways.222 Cell Stem Cell 6, 215–226, March 5, 2010 ª2010 Elsevier Inc.DISCUSSION
NANOG is a direct downstream target of
SMAD2/3 signaling in hESCs. However,
several (putative) binding sites in the
Nanog promoter are not well conserved
in the mouse (Greber et al., 2008; Vallier
et al., 2009a; Xu et al., 2008). This led
to speculation that there may be a
species-specific difference in regulatory
pathways (in Greber et al., 2008). How-
ever, one putative binding site, whichhas been overlooked in two independent studies, is present in
the mouse Nanog promoter several bp upstream of the known
SOX-OCT bipartite motif. Our data suggest that this site is func-
tional in EpiSCs and that SMAD2/3 signaling occurs upstream of
Nanog in EpiSCs, as in hESCs (Figures 7D and 2). SMAD2/3
signaling is likely to be a key mechanism in the self-renewal of
EpiSCs, because inactivation of the pathway promotes neuroec-
todermal differentiation in both hESCs and EpiSCs, which can be
prevented by constitutive Nanog expression (Greber et al., 2008;
Smith et al., 2008; Tesar et al., 2007; Vallier et al., 2009a). Nodal
is likely to be the major autocrine factor responsible for activating
the SMAD2/3 pathway, which acts to maintain the pluripotent
epiblast cell state, consistent with findings in vivo (Figure 2;
Camus et al., 2006).
We find that FGF2 addition has an inhibitory effect on neuroec-
todermal induction—particularly on PAX6/Pax6 expression—in
both hESCs and EpiSCs, an effect that is nota bene totally
distinct from the well-known role of FGF2 in supporting the self-
renewal of neural stem cells (Figures 3D and 3E; Figure S3;
Figure 7. Early Gene Expression Signatures
in mESCs Differentiating to an Epiblast-like
State
(A) Short-term stimulated feeder-free OG2 ESCs
analyzed by expression microarrays. Gene
symbols in gray are known downstream targets
of the manipulated pathways. Klf4 (represented
by three different probes) was downregulated by
LIF/STAT3 inhibition rather than by FGF/ERK acti-
vation, whereas Klf2 was repressed by FGF/ERK
stimulation rather than by LIF/STAT3 inhibition.
(B) Morphology of OG2 ESCs treated for 2 days in
the indicated ways.
(C) RT-qPCR analysis of samples treated as in (B).
Socs3 is a known LIF/STAT3 target gene, whereas
Egr1 served as a control to monitor FGF/ERK
activity. Bars: SEM between independent experi-
ments.
(D) Model summarizing the control of fate deci-
sions in EpiSCs by signaling pathways. See text
for discussion. The contribution of CH with-
drawal/Wnt suppression in promoting epiblast
differentiation from ESCs was not investigated.
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EpiSCs can be enhanced by inhibiting both SMAD2/3 and
FGF/ERK signaling. In hESCs, but apparently not in EpiSCs,
additional suppression of endogenous BMP signaling may be
required to increase the differentiation specificity and fully reveal
the inhibitory effect of FGF/ERK signaling (Figure S3B and asso-
ciated text, Figure S3D). FGF-mediated inhibition of neuroecto-
dermal gene expression in hESCs and EpiSCs can contribute
to the maintenance of the undifferentiated state (Figure 7D).
However, FGF2 supplementation of culture media cannot fully
block neuroectodermal commitment, a fact that may help
address the discrepancy between our conclusions and those
drawn by others (Vallier et al., 2009a, 2009b; Figure S3B and
associated text).
FGF/ERK signaling also plays a more positively acting role in
hESCs: namely to support NANOG expression (Figure 4). The
precise mechanism underlying this aspect of FGF2 action is
not understood. Nonetheless, we believe that the previously
recognized cooperation between FGF/ERK and SMAD2/3 path-
ways in supporting hESC self-renewal (Vallier et al., 2005) culmi-
nates in the activation of NANOG as a shared target. However,
the effect of SMAD2/3 signaling onNANOG expression in hESCs
is dominant, so that the contribution of FGF2 is overshadowed
and becomes apparent only in defined media lacking any
SMAD2/3-stimulating factors. Interestingly, the FGF2 geneCell Stem Cell 6, 215–2appears to be directly controlled by
OCT4, suggesting the presence of an
autocrine loop that helps to sustain self-
renewal in hESCs, which may involve all
pleiotropic downstream effects of FGF2
signaling described to date (Figure 4;
Bendall et al., 2007; Boyer et al., 2005; Ei-
selleova et al., 2009; Greber et al., 2007;
Li et al., 2007; Ludwig et al., 2006). In
contrast, FGF2 signaling does not seem
to actively promote self-renewal viaNanog expression in EpiSCs, according to our assays with
feeder-free conditions. The situation is different when EpiSCs
are grown on MEFs, because FGF2 enhances the secretion of
ActA from these cells, thus acting indirectly through another
pathway. However, our data suggest that the active and direct
role of FGF2 signaling in supporting self-renewal through
NANOG is specific to human ESCs and not shared with EpiSCs.
The shear existence of a hESC-specific feature is, in principle,
not very surprising considering that hESCs are equivalent to
neither mESCs nor to EpiSCs (they appear to share features
with both cell types, see above) and that there are notable differ-
ences in early development between mouse and human (Larsen,
2001; Nagy et al., 2003). We cannot rule out the possibility that
FGF signaling may activate the expression of target genes other
than Nanog to sustain self-renewal in EpiSCs.
EpiSCs can be reverted back to an ESC-like state in vitro by
the overexpression of Klf4 (Guo et al., 2009). This is a very
perspicuous finding, because (1) Klf4 is one of Yamanaka’s
reprogramming factors (Takahashi and Yamanaka, 2006), (2)
KLF4 is an integral component of the mESC self-renewal
network (Chen et al., 2008; Jiang et al., 2008), and (3) EpiSCs
virtually do not express Klf4. Recent data by Hanna et al.
(2009) suggested that a stringent mESC medium alone could
be sufficient to revert EpiSCs to an ESC-like state. It is probable
that a MEF feeder layer facilitates this process, because it is26, March 5, 2010 ª2010 Elsevier Inc. 223
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Roles of SMAD2/3 and FGF Signaling in EpiSCsa substrate supporting the growth of both ESCs and EpiSCs. We
have reverted several EpiSC lines via PD/CH/LIF-containing
medium and demonstrate that the resultant cells exhibit
ESC-specific properties and developmental potential. Reversion
efficiencies with the hybrid E3 line were sufficiently high to inves-
tigate the medium-induced effects on gene expression. Irre-
spective of the mechanism (direct versus indirect), FGF/ERK
suppression, GSK3b inhibition, and LIF/STAT3 activation ap-
peared to cooperate in reverting the EpiSCs. GSK3b inhibition
selected against the epiblast state by inducing (mesendodermal)
differentiation in many, but not all, cells, consistent with the
prominent role of WNT/b-catenin signaling in mammalian gastru-
lation (Figure 7D; Murry and Keller, 2008; Sumi et al., 2008). LIF
appeared to make a contribution at later stages, perhaps by
stabilizing the reverted state, because LIF treatment alone did
not immediately induce the expression of any ESC-specific
genes but was most productive over the long term (Figure 6A).
However, cooperation between the three molecules was most
evident in the induction of Klf2, whereas FGF/ERK suppression
had the strongest immediate-early effect on Klf2 expression
(Figure 7D). Klf2 can substitute for Klf4 in direct reprogramming
experiments, and Klf4 or Klf2 overexpression enables EpiSC
reversion (Guo et al., 2009; Hall et al., 2009; Nakagawa et al.,
2008). Moreover, knockdown of Klf2 in EpiSCs impaired rever-
sion efficiencies (Figure 6D). Given that ESCs tolerate Klf2
silencing (Jiang et al., 2008), these data therefore suggest that
medium switch-based reversion of EpiSCs may at least partly
constitute an inductive process involving KLF2. This would not
be based on replacing the function of a reprogramming factor
with small molecules but on inducing its endogenous expression
by manipulating the activities of signaling pathways.
Kru¨ppel-like transcription factors (Klfs) are upstream regula-
tors of Nanog expression in ESCs (Jiang et al., 2008). Because
EpiSCs express much lower levels of Klf2 and Klf4 but rather
depend on SMAD2/3 signaling to drive Nanog expression, it
appears that a transition from the ES to the epiblast cell state
must also involve a switch in Nanog regulation. The effect of
FGF/ERK signaling on repressing Klf2 was consistent in EpiSCs
and mESCs. In contrast, LIF stimulation had a positive effect on
Klf4expression only in ESCs. Consequently, LIF/STAT3 suppres-
sion and FGF/ERK stimulation had a cooperative effect in dimin-
ishing both Klfs in ESCs (Figure 7D). It is quite possible that
withdrawal of the GSK3b inhibitor is also a contributing factor
(data not shown). The levels of Fgf5, a marker for the epiblast
state, were also increased in a cooperative way. Interestingly, it
has been revealed that the Fgf5 gene is a repressed direct target
of Klfs in mESCs (Jiang et al., 2008), underscoring the importance
of downregulation of Klfs during the ES-Epi cell transition.
The model in Figure 7D suggests that there is an equilibrium
between the ES and epiblast cell states, the precise position of
which is dictated by the culture conditions. This may be more
evident for so-called nonpermissive mouse strains than for 129
inbred cells (Hanna et al., 2009). A recent report by Bao et al.
(2009) describing the generation of mESC-like cells from EpiSCs
grown under low-stringency mESC culture conditions supports
the equilibrium concept. Our data confirm that LIF treatment
alone can give rise to ESC-like colonies. However, EpiSC rever-
sion efficiencies were significantly higher when blocking FGF/
ERK and GSK3b in addition, underscoring the idea of coopera-224 Cell Stem Cell 6, 215–226, March 5, 2010 ª2010 Elsevier Inc.tion among the three molecules (Figure 5A; Figure S6). The
model further implies that somatic cell lineage commitment
always commences from the epiblast and not from the ES cell
state, in accordance with the in vivo situation. Work by Kunath
et al. (2007) revealed that Fgf4/ or Erk2/ ESCs are deficient
in somatic cell lineage commitment. According to the model in
Figure 7D, such cells could become stuck halfway between the
ES and epiblast cell states. Finally, the model does not question
data by Ying et al. (2003) suggesting that FGF/ERK signaling is
required for neuroectodermal induction in ESCs, as this differen-
tiation process appears to be composed of at least two steps
(J.S., unpublished data): the first step (ES-Epi) would be
promoted by FGF/ERK, whereas the second (Epi-Neuro) would
be inhibited, but not blocked, by FGF/ERK signaling (Figure 7D).
Taken together, our data are consistent with published findings
and extend the current model of cell fate decisions concerning




Hybrid E3 EpiSCs were derived from day 5.5 epiblasts generated by mating
homozygous GOF18-EGFP male mice (Yoshimizu et al., 1999; C57Bl/6 and
DBA/2 background) with 129/Sv female mice. The activity of the Oct4-GFP
transgene was gradually silenced over time for unknown reasons, whereas
that of endogenous Oct4 was stable. After initial mechanical passaging on
MEFs (strain CF1), cells were split with collagenase IV. KSR medium contained
20% Knockout Serum Replacement and was supplemented with 5 ng/ml
FGF2 to yield ‘‘unconditioned medium’’ (UM; Amit et al., 2004). For feeder-
free culture, cells were adapted to grow in MEF-conditioned medium (CM;
Xu et al., 2001) on FCS-coated dishes. Some experiments were carried out
in defined N2B27 medium (Yao et al., 2006). Human ESCs (H1, H9, HuES6;
Cowan et al., 2004; Thomson et al., 1998) were treated in N2B27 medium.
Mouse ESCs or reverted EpiSCs were grown on MEFs or on gelatin-coated
plates in KSR medium wherein the specified factors were added. Reverted
E3 EpiSCs displayed reactivation of the Oct4-GFP transgene.
RT-qPCR and Microarray Analysis
Cells for RNA isolation were usually lysed directly in the culture wells. Reverse
transcription was done with MMLV enzyme (USB) and oligo dT15 priming.
qPCR was carried out with SYBR Green mix (ABI). All qPCR primers were
validated with respect to efficiency and specificity (Table S6). Calculations
were based on the DDCt method employing two housekeeping genes for
normalization.
cRNA samples for global gene expression analyses were prepared with the
linear TotalPrep RNA Amplification Kit (Ambion). Hybridizations on mouse-8
V2 chips (Illumina) were carried out as recommended by the manufacturer.
Data analysis was done in BeadStudio and MS Excel.
Immunoblotting and ChIP-qPCR
Cells for western blotting were rapidly harvested by scraping in culture
medium, pelleted, and lysed on ice, if necessary, to preserve the phosphory-
lation status of the proteins. Electrophoresis, blotting, and antibody incuba-
tions were carried out according to standard procedures.
For ChIP-qPCR, we adopted and scaled down a published protocol (Lee
et al., 2006). Fold enrichment was calculated with the DDCt method, by
normalizing Ct values against two (human) or three (mouse) independent
genomic reference loci and comparing them to the input sample set to 1-fold.
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